Urology Times staff

“One of the things that distinguishes this treatment is its patient and provider ease of delivery,” says Boorjian.

The ongoing trial is enrolling patients at 62 locations in the United States and worldwide.

The FDA recently approved a less-frequent, fixed dose of durvalumab at 1500 mg every 4 weeks for use in patients with metastatic urothelial carcinoma.

The FDA approved darolutamide in July 2019 for the treatment of patients with nonmetastatic castration-resistant prostate cancer, based on findings from the phase 3 ARAMIS trial.

In this interview, Emmanuel S. Antonarakis, MD, provides an overview of rucaparib (Rubraca) and olaparib (Lynparza), discusses the key trials that led to their approvals, and explains the urologist’s role in their use.

“We continue to see a building story of benefit of statin medications in men who have prostate cancer,” says Robert J. Hamilton, MD, MPH.

Williams discusses a study comparing costs for radical versus partial cystectomy.

Chris Du, MD, discusses findings from a study published in Neurourology and Urodynamics.

Investigators evaluated uropathogen prevalence and antibiotic resistance in a urogynecologic patient population.

Attorney Kenton H. Steele, Esq, discusses his recent Urology Times® column.

Kathleen Kieran, MD, MSc, MME, discusses findings from a recent paper published in Urology.

Rena Malik, MD, discusses findings from a recent Urology Practice study.

Researchers evaluated the use of interprofessional consultations within the specialty of urology.

Adam J. Gadzinski, MD, MS, highlights positive outcomes of telemedicine multidisciplinary urologic cancer clinics implemented by the University of Washington/Seattle Cancer Care Alliance.

Only 5% of websites studied discuss risks of treatments, investigators found.

Ramaprasad Srinivasan, MD, PhD, provides background on the prognosis and treatment of patients with Von Hippel-Lindau–associated renal cell carcinoma and highlights the novel agent MK-6482.

Register for a live, interactive event featuring leaders in oncology reviewing and discussing patient cases in Bladder Cancer/Renal Carcinoma.

Vikram M. Narayan, MD, discusses the high complete response rate and manageable safety profile with nadofaragene firadenovec in BCG-unresponsive non-muscle invasive bladder cancer.

Vikram M. Narayan, MD, discusses how smoking is the most significant known risk factor for bladder cancer.

Reza Z. Goharderakhshan, MD, discusses how patient compliance for recommended studies increased from less than 10% to 82% following implementation of the program.

On the latest episode of the Speaking of Urology podcast, Dr. Giulia Lane discusses her recent study evaluating treatment of urethral stricture disease in women.

“Listen. Be emphatic. Be transparent,” Pansy Uberoi, MD, MPH, advises in this interview.

Urologist Adam J. Gadzinski, MD, MS, shares his excitement about the dawn of the precision medicine era in prostate cancer.

Steele outlines topics covered in his recent column, "Why urologists should beware the perils of friendly prescribing."

Declan G. Murphy, MB BCh, discusses how PSMA PET/CT imaging often leads to the upstaging of a patient’s prostate tumor, as well as how the novel technique lowers the rate of equivocal findings.